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The elicitation of broadly neutralizing antibodies directed against the human immunodeficiency virus type 1 (HIV-1) envelope
glycoproteins, gp120 and gp41, remains a major challenge. Attempts to utilize monomeric gp120 as an immunogen to elicit high titers of
neutralizing antibodies have been disappointing. Envelope glycoprotein constructs that better reflect the trimeric structure of the functional
envelope spike have exhibited improved immunogenicity compared with monomeric gp120. We have described soluble gp140 ectodomain
constructs with a heterologous trimerization motif; these have previously been shown to elicit antibodies in mice that were able to neutralize a
number of HIV-1 isolates, among them primary isolate viruses. Recently, solid-phase proteoliposomes retaining the envelope glycoproteins
as trimeric spikes in a physiologic membrane setting have been described. Here, we compare the immunogenic properties of these two
trimeric envelope glycoprotein formulations and monomeric gp120 in rabbits. Both trimeric envelope glycoprotein preparations generated
neutralizing antibodies more effectively than gp120. In contrast to monomeric gp120, the trimeric envelope glycoproteins elicited
neutralizing antibodies with some breadth of neutralization. Furthermore, repeated boosting with the soluble trimeric formulations resulted in
an increase in potency that allowed neutralization of a subset of neutralization-resistant HIV-1 primary isolates. We demonstrate that the
neutralization is concentration-dependent, is mediated by serum IgG and that the major portion of the neutralizing activity is not directed
against the gp120 V3 loop. Thus, mimics of the trimeric envelope glycoprotein spike described here elicit HIV-1-neutralizing antibodies that
could contribute to a protective immune response and provide platforms for further modifications to improve the efficiency of this process.
Published by Elsevier Inc.
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For HIV-1, the elicitation of neutralizing antibodies with the
potency to inhibit primary viral isolates and the breadth to
recognize different viral strains is inefficient. Vaccination
strategies that elicit high levels of broadly reactive neutral-
izing antibodies would be extremely desirable.
Evidence for a protective role of neutralizing antibodies
against HIV-1 infection comes primarily from passive
transfer studies. A number of neutralizing antibodies and
combinations thereof have been examined for their ability to
protect rhesus macaques or chimpanzees from viral chal-
lenge. Neutralizing antibodies administered prior to viral005) 33–46
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infection with HIV-1, simian immunodeficiency virus (SIV),
or a chimeric simian-human immunodeficiency virus
(SHIV) (Berman et al., 1990; Mascola et al., 1999, 2000;
Parren et al., 2001). In animals that did become infected,
peak viremia was diminished, which is a prognostic
indicator of slow disease progression. In a number of
vaccinated animals, the levels of vaccine-induced neutraliz-
ing antibodies correlated with protection and a lower virus
load (Berman et al., 1990; Bruck et al., 1994). In some HIV-
1-infected long-term nonprogressors, exceptionally high
titers of broadly neutralizing antibodies have been detected
(Pilgrim et al., 1997).
As a result of HIV-1 infection, a vigorous antiviral
immune response occurs. Despite this immune response,
progression to acquired immunodeficiency syndrome
(AIDS) generally ensues after many years of infection.
The selective pressure exerted by the humoral response is
highlighted by the difference in neutralization sensitivity
that can be observed between T-cell-line adapted (TCLA)
isolates and primary isolates (Daar et al., 1990; Mascola et
al., 1994; Moore et al., 1992; Wrin et al., 1995; Zhang et al.,
1997).
The major targets for HIV-1-neutralizing antibodies are
the envelope glycoproteins, gp120 and gp41. The prepon-
derance of evidence indicates that these envelope glyco-
proteins are organized into trimeric spikes on the viral
surface and, as such, are the only viral proteins accessible to
the humoral immune system on virions. The complex
organization of gp41 and gp120 as trimers of heterodimers
has important implications for immune diversion. It has
been suggested that in vivo, disassembled envelope glyco-
protein spikes or viral debris may be the predominant
immunogen (Parren et al., 1997). The interaction of gp41
and gp120 is noncovalent, thought to be labile, and allows
gp120 to be shed from the functional spike. Upon
disassembly of the glycoprotein complexes, many surfaces
that are occluded on the functional trimer are presented to
the immune system. Both gp120 and gp41 may also change
conformation upon dissociation. As a consequence, many
antibodies elicited in vivo are raised against these decoy
epitopes and do not bind the functional envelope glyco-
protein complex (reviewed in (Wyatt and Sodroski, 1998)).
It has also been suggested that monomeric gp120 in its free
state is a very flexible molecule (Myszka et al., 2000). HIV-1
gp120 may sample many conformations and present a
multitude of different conformations to the humoral
immune system, many of which may be irrelevant for virus
neutralization.
The anticipation of similar immunogenic properties of
the native trimeric HIV-1 envelope glycoprotein complex
and monomeric gp120 and the relative ease of production of
gp120 led to the utilization of gp120 as an immunogen in
many animal and human trials. To date, all gp120-based
immunogens have been disappointing in their ability to
elicit broadly neutralizing antibodies (Barnett et al., 1997;Belshe et al., 1998; Berman et al., 1990; Connor et al., 1998;
Mascola et al., 1996; Wrin et al., 1995). Consistent with
this, gp120 has not demonstrated efficacy in eliciting
protection against HIV-1 (Vaxgen trial announcement).
An understanding of the mechanistic basis for the poor
immunogenic potential of gp120 has led to the design of
immunogens based on the trimeric envelope glycoprotein
complex. Neutralization by antibodies has in some cases
been shown to correlate with binding to envelope glyco-
protein complexes, but not to monomeric gp120. This
suggests that, conversely, neutralizing antibodies might be
better elicited by moieties that mimic the functional HIV-1
envelope glycoprotein trimer (Fouts et al., 1997; Roben et
al., 1994; Sattentau and Moore, 1995; Sullivan et al., 1995).
Several approaches have been taken to stabilize the labile
HIV-1 envelope glycoprotein complexes. A number of
constructs consisting of the gp120 and gp41 ectodomains
have been generated (Earl et al., 1994; Farzan et al., 1998;
Yang et al., 2000a, 2001, 2002). In most of these soluble
ectodomain constructs the gp120–gp41 cleavage site was
modified to prevent shedding of gp120 from the complex. In
some cases, soluble HIV-1 envelope glycoprotein ectodo-
main constructs have been made with intact gp120–gp41
cleavage sites by introducing disulfide bonds between
gp120 and gp41 subunits (Binley et al., 2000). Even with
disruption of gp120–gp41 proteolytic cleavage, soluble
HIV-1 envelope glycoproteins assemble into several oligo-
meric states, including dimers and tetramers. The C-terminal
introduction of heterologous trimerization domains dramat-
ically improves the stability and homogeneity of soluble
HIV-1 envelope glycoprotein trimers (Yang et al., 2000b,
2002). One soluble ectodomain construct contains a
heterologous trimerization domain derived from the yeast
transcription factor GCN4 (Yang et al., 2000b) appended to
the envelope glycoprotein from the highly neutralization-
resistant primary isolate YU2 (Li et al., 1991). This soluble
ectodomain construct, YU2 gp140 (/GCN4), has been
shown to elicit neutralizing antibodies with some breadth in
mice (Yang et al., 2001). The amount of serum obtained in
these experiments, however, limited the testing of a broad
panel of HIV-1 isolates and characterization of the
neutralizing activity in these sera.
In an attempt to present trimeric HIV-1 envelope
glycoprotein complexes in a more natural context, we have
generated solid-phase proteoliposomes (PLs) containing
cleavage-defective HIV-1 envelope glycoproteins derived
from the primary isolate YU2 (EnvPLs) (Grundner et al.,
2002). The EnvPLs allow for the simultaneous capture and
purification of envelope glycoproteins on a solid support
and the reconstitution of a lipid membrane. The membrane-
anchored HIV-1 envelope glycoproteins in PLs antigenically
resemble the envelope glycoproteins expressed on the
surface of cells (Grundner et al., 2002). Here, we sought
to compare the immunogenic properties of YU2 gp120,
YU2 gp140 (/GCN4), and EnvPLs in rabbits. In this
study, the soluble YU2 gp140 (/GCN4) trimers elicited
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YU2 virus and heterologous primary isolates. The EnvPLs
elicited broadly neutralizing antibodies better than gp120,
although this activity was less potent and broad than that
seen in the sera from animals immunized with the YU2
gp140 (/GCN4) proteins. In this study, we also analyze
the neutralizing capacity of the serum IgG from the gp140
(/GCN4) and EnvPL-immunized rabbits and begin the
initial mapping of the neutralization specificity. Interest-
ingly, in most animals, the majority of the neutralizing
antibody response elicited by these trimeric immunogens
was not directed against the V3 loop of either homologous
or heterologous virus. These findings support the hypoth-
esis that trimeric envelope glycoprotein formulations
represent an advance over gp120-based immunogens in
eliciting neutralizing antibodies.Results
The immunogenicity of YU2 gp120, gp140 (/GCN4)
and EnvPLs was tested in rabbits. The molecular clone YU2
was chosen for the preparation of EnvPLs for immunization
studies because it exhibits one of the most neutralization-
resistant phenotypes. This molecular clone was not pas-
saged in tissue culture prior to molecular cloning (Li et al.,
1991) and is relatively resistant to neutralization by
antibodies and soluble forms of the CD4 receptor. We
hypothesized that breadth of neutralization would most
likely be exhibited by antibodies that are raised against
neutralization-resistant molecular clones, with neutralization
extending from there to more neutralization-sensitive
clones. This expectation is supported by a previous study
in mice, which demonstrated that soluble trimers based on
the YU2 envelope glycoprotein were more effective at
eliciting neutralizing antibodies against primary HIV-1
isolates than trimers based on the TCLA HXBc2 envelope
glycoprotein (Yang et al., 2001).Fig. 1. Schematic diagram of rabbit immunization protocol. The numbers of inocu
Within each group designation, the horizontal line(s) indicate repeated administr
terminated; an arrowhead indicates that the group will undergo further analysis.The immunization protocol consisted of a priming
inoculation followed by subsequent inoculations at 2, 6,
10, 22, and 34 weeks after priming (Fig. 1). After the 4th
inoculation, sera were collected 7 to 10 days post-injection
and were assessed for binding to gp120 by ELISA and
subsequently for HIV-1 neutralizing reactivity. All groups
except group E generated high anti-gp120 IgG antibody
titers with endpoint titers of 12,500–62,500 (see ELISA data
in Table 1). The rabbits immunized sequentially with
EnvPLs containing envelope glycoproteins from different
HIV-1 strains (group E) exhibited only low or no reactivity
with YU2 gp120. One of the animals (rabbit 19) in group C
also made a poor response against YU2 gp120 (Table 1).
Anti-HIV-1-neutralizing activity of sera after four
inoculations
To assess neutralizing activity in the sera, 1:5 dilutions of
pre-immune and immune serum obtained after four inocu-
lations were tested in a single-round neutralization assay
(Mascola et al., 2002b) against the clade B molecular clones
HXBc2, SF162, BaL, 89.6, ADA, and YU2 (Table 1). It is
worth noting that although a 1:5 dilution of serum is the
lowest serum dilution practically achievable in this assay, it
is still 5-fold less than the serum concentration present in
vivo. We purposely selected a set of viruses representing a
range of neutralization phenotypes, with increasing resist-
ance from the TCLA isolate HXBc2 to the primary isolate
YU2. The relative resistance of these isolates is reflected in
the necessary amount of the monoclonal antibodies 2F5 and
2G12 or a mixture of IgG purified from sera of HIV-1-
infected individuals (HIV-IG) required for virus neutraliza-
tion (Table 2).
The weakest neutralizing activity was found in the YU2
gp120 group (group A), with only two animals generating
antibodies neutralizing N50% of infection with the isolate
SF162, the most neutralization-sensitive of the primary
isolates tested. No homologous neutralization of the YU2lations and the bleeds are indicated for each of five groups of rabbits (A–E).
ation of the same immunogen. A vertical bar indicates that the group was
Table 1
Envelope glycoprotein reactivity and neutralizing ability of sera inoculated rabbitsa
a HIV-1 single round in vitro neutralization using rabbit serum at a 1:5 dilution against a panel of viral isolates. Serum was collected after four inoculations.
Numbers under viral isolates indicate % neutralization, which was determined as follows. The effect of individual pre-immune serum on infection was
determined using the reactivity of individual pre-immune sera as baseline neutralization. Color-coded light blue boxes indicate 50–80% neutralization; dark
blue, N80% neutralization. Asterisk indicates neutralization observed against unusually high enhancement of infection with pre-immune serum. Endpoint
ELISA titers were defined as last reciprocal serum dilution at which a signal of greater than two-fold over the signal of pre-immune serum was detected. The
symbols represent endpoint titers: (+++) 62,500, (++) 12,500, (+) 2500, (+/) 2500–500, and () less than 500. ND: not determined. The values reported are
from a single representative experiment performed in duplicate.
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serum from this group consistently enhanced infectivity of
the YU2 isolate (Table 1).
The group B animals inoculated with YU2 gp140 (/
GCN4) exhibited the greatest degree of both homologous
and heterologous neutralization (Table 1). Three out of
four animals significantly neutralized the isolates, HXBc2,
SF162, and YU2, with one of the animals (#14) neutraliz-
ing both HXBc2 and YU2 and one animal (#15) HXBc2
and SF162 by more than 80%. By comparison, 1 mg/ml of
a mixture of HIV-IG was required in the same experiment
to neutralize infection of the HXBc2, SF162, and YU2
viruses by 97% 94%, and 65%, respectively (this
represents an approximate 1:10 dilution of normal serum
IgG concentrations; Table 2). To achieve neutralization of
N90% of the HXBc2 isolate, 0.5 and 5 Ag/ml of the potent
neutralizing monoclonal antibodies 2F5 and 2G12, respec-
tively, were required. To achieve N90% neutralization of
SF162, 50 Ag/ml 2F5 were required; 2G12 neutralized the
SF162 isolate by only 73% at the highest antibodyconcentration tested (50 Ag/ml) (Table 2). Greater than
50% neutralization of the primary isolates 89.6, BaL, and
ADA by rabbit sera was not observed. To overcome the
limitations of the amount of protein that could be
inoculated into each animal in the EnvPL format, one
group of rabbits (group C) received two inoculations of 25
Ag of YU2 gp140 (/GCN4) followed by two inoculations
of YU2 EnvPLs. In this group, only two animals displayed
neutralizing activity greater than 50% with one and two
viruses, respectively (Table 1). Rabbit 21 showed the
greatest homologous neutralization of the YU2 isolate of
all rabbits with 96% neutralization. This neutralizing
activity, however, crossed over only to the SF162 isolate,
which was neutralized by 64%. Overall, the neutralizing
reactivity in this group was markedly poorer than that in
the group inoculated with YU2 gp140 (/GCN4) glyco-
proteins alone.
In the group (group D) inoculated with YU2 EnvPLs, all
five animals displayed neutralizing activity greater than
50% against at least two viral isolates. Animal 24 may be
Table 2
Effects of selected antibodies on the FACS-based neutralization assaya
Ab Concentration % Neutralization
(Ag/ml)
Viral isolate
HXBc2* SF162 89.6 BaL ADA YU2
HIV-IG 10,000 ND 100 100 99 97 100
1000 97 94 81 71 75 65
2F5 50 ND 94 93 78 86 95
5 100 71 53 41 47 63
2G12 50 ND 73 84 81 24 1
5 96 60 62 62 8 1
a HIV-1 single-round in vitro neutralization assay using HIV-IG and monoclonal anti-envelope glycoprotein antibodies (Ab) against a panel of viral isolates.
Numbers indicate % neutralization. Data were obtained in the same experiment as data in Table 2. (*) For the neutralization of HXBc2, 10-fold lower
concentrations of HIV-IG and monoclonal antibodies than indicated were used.
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activity of 83% and 94% against isolates 89.6 and SF162,
respectively, are likely due to the unusual and unexpected
enhancing effect detected in pre-immune serum of this
animal (281% and 225%). This unexplained enhance-
ment may artificially elevate neutralization values that we
have reported for this one animal due to the manner in
which we calculate % neutralization. That is, we calculate %
neutralization relative to the pre-bleed value, which in this
case is negative. This adjustment then sets the bzero pointQ
at a relatively low level that could possibly lead to an
overestimate of the actual neutralizing activity present and
therefore the values reported should be interpreted with
caution for this particular serum sample. Only one animal
significantly neutralized the YU2 isolate (animal 23 with
78% neutralization), while other animals showed little
neutralization (animals 22 and 26). Overall, the neutraliza-
tion activity of sera from this group, when achieved, was
weaker than that observed in the animals inoculated with
YU2 gp140 (/GCN4) glycoproteins.
The sequential inoculation of the group E rabbits with
different envelope glycoprotein EnvPLs was designed to
focus the immune response on the conserved elements
common to the four clade B envelope glycoproteins. This
group displayed the lowest anti-gp120 titers as determined
by ELISA (Table 1). This may be a consequence of a lower
envelope glycoprotein dose in this group due to less
efficient JR-FL envelope glycoprotein incorporation into
EnvPLs as analyzed by FACS and gels (data not shown).
Very limited neutralizing activity was observed in this
group, with sera exhibiting enhancement of YU2 infection
and only weak neutralization of SF162 (animals 28, 30, 31)
and HXBc2 (animal 30). The poorer neutralization activity
exhibited by these sera probably reflects the lower overQ
all titers of anti-gp120 binding antibodies present in the
sera.
By both inspection (see Fig. 1S, Supplementary Infor-
mation) and statistical analysis of the neutralizing profiles
elicited by monomeric YU2 gp120 as compared to the YU2
gp140 (/GCN4) trimers, we concluded that the gp140molecules were a superior immunogen. By inspection of the
percentage neutralization of the HXBc2 and SF162 isolates,
we also concluded that the EnvPLs elicited better responses
than monomeric gp120. Statistical analysis was done
comparing neutralization of HXBc2, YU2, and SF162 by
the sera from groups A versus B by a two-tailed Student’s t
test. Statistical significance was achieved comparing
HXBc2 neutralization between the two groups (mean for
gp120 monomer 32 F 5; mean for gp140 (/GCN4) 69 F
8, P b 0.005) and if we assigned a value of 1 to the negative
values in the YU2 gp120 group, high statistical significance
was also achieved (mean for the gp120 of 1; mean for the
gp140 (/GCN4) of 56.5; P = 0.01). For the SF162
comparison, the mean for the gp120 group was 37 F 8 as
compared to 66 F 13 for the gp140 (/GCN4) group, but
was not statistically significant (P b 0.09). Collectively,
these data support our conclusions.
HIV-1-neutralizing reactivity in rabbit sera after repeated
boosting
To assess if additional boosting could further increase
neutralizing antibody titers, animals from groups B (gp140
(/GCN4) glycoproteins) and D (EnvPLs), which had
demonstrated a neutralizing antibody response after four
inoculations, were rested for 3 months and additionally
boosted. A second 3-month rest and boost followed (Fig. 1,
inoculations 5 and 6). Only one animal from the group
inoculated with YU2 gp120 was inoculated for a fifth time as
a control. This animal had shown the highest overall
neutralizing activity among the animals in this group (group
A, Table 1). While the fifth inoculation for the animals from
groups B and D consisted of YU2 gp140 (/GCN4) and YU2
EnvPLs as in the previous inoculations, the sixth inoculation
consisted of YU2 gp140 (/GCN4) for all animals in both
groups B (nos. 12, 14–16) and D (nos. 22–26). After
boosting, the anti-gp120 IgG titers, as determined by ELISA,
showed little increase in most sera. The highest increases in
titers from boost 3 to boost 5 were observed in sera from
rabbit 12 (34%), rabbit 14 (14%), rabbit 22 (27%), and rabbit
C. Grundner et al. / Virology 331 (2005) 33–463825 (18%). For all other animals, the increase in gp120
reactivity was below 10% (data not shown).
A consistent boosting effect could be observed on the
neutralizing activity in most sera primed and boosted with
the oligomeric glycoproteins (Table 3). When the neutraliz-
ing activity against the initial set of clade B viral isolates in
the sera after inoculations 4, 5, and 6 were compared, the
neutralizing activity in the sera increased from inoculations
4 to 6 in all animals except rabbit 15 (Table 3). In serum
from this animal, the neutralizing activity against HXBc2,
SF162, and 89.6 was already significant after the 4th
inoculation and remained relatively constant after inocu-
lations 5 and 6. An increase in neutralizing activity by over
30% could be readily detected in some animals after
inoculations 5 and 6. Notably, neutralization of the 89.6
isolate could now be observed in three of the four animals
inoculated with YU2 gp140 (/GCN4). The animal
inoculated with gp120, in contrast, lost all neutralizing
activity in the course of the repeated boosting regimenTable 3
Neutralizing activity of sera from rabbits after additional boostinga
a HIV-1 single-round in vitro neutralization assay using rabbit serum (4th, 5th, and
indicate % neutralization. Serum was collected after each inoculation 4, 5, or 6 for
for Table 1. Color-coded light blue boxes indicate 50–80% neutralization; dark b(Table 3). In summary, the neutralizing breadth and potency
of the majority of tested sera increased with additional
inoculations. With the exception of one virus/serum pair
(YU2 and serum from rabbit 15, sixth inoculation), serum at
a 1:5 dilution from three out of four animals in the group
inoculated with YU2 gp140 (/GCN4) neutralized all HIV-
1 isolates tested in this experiment by more than 50%. For
all virus/serum pairs in the group inoculated with YU2
EnvPLs that displayed neutralizing activity greater than
50% after four inoculations, the neutralizing activity
increased after two additional inoculations. Three other
virus/serum pairs in this group exhibited neutralizing
activity after six inoculations, where none greater than
50% had been detected after four inoculations.
Titration of neutralizing sera after six inoculations
To assess the IC50 of the sera that exhibited neutralizing
activity, sera from rabbits 12, 14, 15, 22, 23, 24, and 266th inoculations) at a 1:5 dilution against a panel of viral isolates. Numbers
each animal as indicated. Percent neutralization was calculated as described
lue, N80% neutralization.
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ing activity. The sera were only tested against viruses that
they could neutralize at a level greater than 50–60% at a 1:5
dilution. Fig. 2A shows a titration of the sera from three of
the Group B rabbits against 4 viruses (HXBc2, SF162, 89.6
and YU2). All sera tested showed a clear dose-response of
viral neutralization similar to the curves in Fig. 2A. IC50
values were derived from these dose-response data (Fig.
2B). Most of the sera tested showed 50% neutralization of
the HXBc2, SF162, 89.6, and YU2 viruses at serum
dilutions greater than 1:30 (Fig. 2B). The TCLA strain
HXBc2 was neutralized at the 50% level by serum dilutions
of 1:123, 1:107, and 1:101 for the three animals inoculated
with YU2 gp140 (/GCN4) that had generated neutralizing
activity in their sera.
Analysis of the neutralizing activity following serum IgG
fractionation
There are often nonspecific effects on viral entry caused
by undefined components in animal sera that could enhance
or obscure immunoglobulin-mediated viral neutralization.
To demonstrate that the dose-dependent neutralizing activity
present in the immune sera after six inoculations was
mediated by immunoglobulin, the IgG was fractionatedFig. 2. Titration of neutralizing activity in sera after six inoculations of
protein. Panel A: sera raised against YU2 gp140 (/GCN4) envelope
glycoprotein was tested for neutralization of different HIV-1 isolates at
decreasing serum concentrations. Panel B: neutralizing antibody titers in
rabbit sera after six inoculations; IC50 values for sera raised against YU2
gp140-GCN4 and YU2 proteoliposomes are shown. Values were derived
from dose–response data shown in Fig. 2A and not shown. ND: not
determined, if the serum did not exhibit significant neutralization of virus at
the highest serum dilution tested.from individual sera and tested for neutralization. As
described in Materials and methods, neutralization assays
were performed in duplicate at an IgG concentration of 10
mg/ml, the normal level of IgG found in sera, to assess the
maximal potency and breadth of neutralization of the
immune sera against a broader array of clade B primary
isolates (Table 4). This concentration of IgG was roughly 5-
fold higher than could be obtained by using non-fractionated
serum at the lowest dilution possible in the neutralization
assay (1:5) and is reflected by the higher IgG neutralization
values obtained relative to the serum values presented in
Table 3. Pre-immune serum IgG was used as a control to
determine the level of non-specific viral neutralization
mediated by immunoglobulins at this concentration. At 10
mg/ml, homologous YU2 neutralization exceeding 75% was
accomplished by three rabbits inoculated with gp140 (/
GCN4) glycoproteins and by three animals immunized with
the EnvPLs (Table 4). Readily detectable heterologous
neutralization by IgG from YU2 gp140 (/GCN4) rabbits
12 and 14 of the primary isolates SF162, 89.6, BaL, JR-
CSF, BR07MC at levels of 69–99% was observed (Table 4).
The IgG from the sera of the rabbit 14 was able to neutralize
ADA at a level of 50%. The remainder of the primary
isolates in the panel could not be neutralized at a level that
we considered significant. Occasionally, enhancement of
viral infection was observed as indicated by the negative
values in Table 4, presumably caused by Env-specific IgG at
sub-saturating concentrations. Including neutralization of
HXBc2 previously observed using sera from animals 12 and
14, the IgG from the two highest neutralizing titer rabbits
(12 and 14) was able to neutralize 8 of 13 isolates tested to a
readily detectable level (Table 4).
We next performed a titration of the neutralization
activity of the purified IgG from sera of the Group B
rabbits against the isolates SF162 and YU2 (see Fig. 2,
Supplementary Information). We were able to obtain IC50
values of the purified IgG after subtraction of any non-
specific neutralization by purified prebleed IgG. The IC50
values for rabbits 12, 14, 15, and 16 against SF162 were
505, b80, 727, and 3812 Ag/ml and against YU2 the IC50
values were 240, 188, 2955, and N10,000 Ag/ml. The
suggestion that sub-saturating concentrations of immune
IgG could induce enhancement of viral entry was evident in
the titration of IgG from rabbit #16. In the sera, this rabbit
had no detectable neutralization activity against YU2. After
IgG purification, weak neutralization was observed and as
the IgG was serially diluted, enhancement of entry was
observed (Fig. 2S, Supplementary Information).
Although all five of the IgG fractions from the EnvPL-
primed and YU2 gp140 (/GCN4) boosted rabbits (group
D) could neutralize SF162 to a reasonable level, these IgG
fractions exhibited less heterologous neutralization against
the more resistant primary isolates. Some apparent neutral-
ization from rabbit 24 against resistant isolates was rendered
suspect due to high levels of enhancement induced by the
pre-immune IgG from this animal.
Table 4
Breadth of neutralization of 12 primary isolates by the purified IgG isolated from the sera of the rabbits immunized six times with YU2 gp140(/GCN4)
glycoproteins and the YU2 EnvPLsa
a Negative numbers indicate enhancement of infection by the IgG. Any non-specific neutralization achieved by pre-immune IgG was first subtracted and all
values here represent neutralization achieved by immune IgG beyond the pre-immune levels. In a few instances, high pre-immune IgG enhancement may have
affected the values*. Color-coded; light blue indicates 50–80% neutralization; dark blue, N80% neutralization.
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To determine if the YU2 gp140 (/GCN4) glycoproteins
had elicited V3 loop-directed neutralizing antibodies, we
performed V3 peptide adsorption studies on the sera that
had exhibited the highest level of neutralizing activity
against the SF162 virus. The SF162 virus was chosen as the
reporter virus since significant neutralization could be
achieved and we assumed that using this virus as the
indicator strain would be more amenable to define the
specificity of the neutralizing activity. The conformation-
sensitive V3 loop antibodies 447-D and 2442 (Gorny et al.,
2002) were used as controls to validate the peptide
adsorption assay. At 50 Ag/ml, the V3 loop antibodies
447-D and 2442 were able to neutralize the SF162 primary
isolate to 95% and 99%, respectively (Fig. 3, left and Table
5). However, when the antibodies were pre-incubated with
the BaL or YU2 V3 loop peptides, but not the control Ebola
peptide, nearly all the neutralizing activity of the two V3
loop antibodies was inhibited (Fig. 3, left and not shown).Fig. 3. Depicted in the figure is V3 loop peptide adsorption assay format, optimi
conformational V3 loop-directed antibody 447-D and adsorption of neutralizatio
immune IgG following six inoculations (rabbits 12, 14 and 15) and partial inhibiNext, we utilized pooled IgG from rabbits 12, 14, and 15 to
determine the peptide concentration range in which all the
neutralizing activity present in the IgG that could be
inhibited by the V3 loop peptides was blocked (Fig. 3,
right). As shown, in the concentration range from 60 to 1.5
Ag/ml, approximately 15% of the pooled immune IgG
neutralizing activity against SF162 was inhibited. Once the
peptide concentration was decreased to 0.15 Ag/ml, full
neutralizing capacity was again observed in the immune IgG
(Fig. 3, right).
When the peptides were used as potential inhibitors of
the SF162 neutralizing activity of sera from animals 12, 13
and 15 (group B), only 25–30% of the neutralizing activity
was removed (Table 5). The level of V3 loop peptide
inhibition was also assayed over a range of anti-serum
dilutions with similar results (Supplementary Information,
Fig. 3S). Similar results were observed for the ability of the
peptides to inhibit the YU2 homologous neutralizing
activity from the sera of the YU2 gp140 (/GCN4) rabbits
(Table 5). We then repeated the V3 loop peptide inhibitionzation and validation. On the left shown is the SF162 neutralization by the
n by V3 loop peptides. On the right is neutralization achieved by pooled
tion of neutralization by the serial dilutions of the YU2 V3 peptide.
Table 5
Neutralization of the SF162 virus and V3 loop peptide adsorptions of the sera elicited by six inoculations of YU2 gp140 (/GCN4) and YU2 EnvPLsa
a Data are compared to mock (no peptide) and scrambled V3 peptide adsorptions, V3 peptide inhibition (Inhib.) values of SF162 neutralization (Neut.) are
shown in red. In the same assay, and as a positive control, the V3 loop antibody 2442 could neutralize SF162 at a level of 100%. When preincubated with 2442,
the YU2 V3 loop peptide could inhibit 95% of this neutralization at a peptide concentration of 15 Ag/ml.
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antisera and analyzed the YU2 EnvPL anti-sera as well
(Table 5). A trend appeared that the EnvPL-elicited serum
antibodies seemed to be slightly more sensitive to V3
peptide adsorption than did the sera elicited by the gp140
(/GCN4) immunogen (Table 5). Interestingly, rabbit 26
anti-sera had approximately 75% of its neutralizing activity
inhibited by YU2 V3 loop preadsorption, but very little
inhibition by preincubation with the scrambled V3 loop
peptide.
When selected individual, purified IgGs were analyzed
by this assay, SF162 neutralization by animal 12 was
inhibited 27% by the V3 loop peptide and animal 26 by
23%, whereas all other IgG samples were inhibited by 8%
or less. Again, no significant neutralization could be
inhibited by the Ebola control peptide (not shown).Discussion
The elicitation of broadly neutralizing antibodies against
the HIV-1 envelope glycoproteins poses a major challenge
for HIV-1 vaccine development. Monomeric gp120 has
proven to be a poor immunogen and to date only a few
envelope glycoprotein formulations have been shown to
elicit broadly neutralizing antibodies more effectively than
monomeric gp120. The complex organization and lability of
the functional trimeric envelope glycoprotein spike pose
difficulties for the design of faithful antigenic mimics. Here,
we tested the ability to elicit neutralizing antibodies in
rabbits of two oligomeric envelope glycoprotein formula-
tions: soluble, stable gp140 (/GCN4) glycoproteins, and
solid-phase EnvPLs containing cleavage-defective, HIV-1
gp160DCT envelope glycoproteins as compared to mono-
meric gp120 as an immunogen. By a series of assays
designed to analyze the neutralizing specificity of the sera,
we show that the trimeric formulations elicit serum anti-
bodies of greater neutralization breadth, that the neutraliza-
tion is dose-dependent, improves upon repeated inoculation,
is IgG-mediated, and importantly, that only a minor fractionof the neutralizing activity is directed against the gp120 V3
loop. We interpret the last observation to indicate that these
trimeric YU2 immunogens present more conserved ele-
ments of the spike to the immune system.
By deriving the envelope glycoproteins for the generation
of EnvPLs from the YU2 molecular clone, the immunoge-
nicity of EnvPLs could be directly compared to that of the
previously tested immunogen YU2gp140 (/GCN4). How-
ever, by SDS gel-based estimates, the dose of envelope
glycoproteins that could be inoculated into rabbits with
soluble YU2gp140 (/GCN4) constructs was approximately
5-fold greater than the amount of envelope glycoproteins
formulated as EnvPLs (data not shown).
To assess the total amount of envelope-directed IgG
antibody elicited by the different immunogens, sera were
tested by anti-gp120 ELISA. Interestingly, although the
dose of envelope glycoproteins administered to animals
receiving EnvPLs was approximately 5-fold lower than the
soluble protein doses, these animals generated endpoint
ELISA titers similar to those of animals inoculated with
soluble envelope glycoproteins (Table 1). The particulate
presentation of envelope glycoproteins in EnvPLs to the
immune system may be more effective for the elicitation of
antibodies than the administration of soluble protein by
either a depot effect or by more efficient uptake of
immunogen by antigen-presenting cells.
After the fourth inoculation, we concluded that the
oligomeric envelope glycoprotein formulations elicited
greater neutralizing activity than did monomeric gp120.
Sera that demonstrated homologous neutralization of the
YU2 virus generally neutralized the SF162 isolate and, in
most cases, the HXBc2 isolate. However, neutralization of
HXBc2 or SF162 did not necessarily imply homologous
YU2 neutralization. This observation is consistent with the
initial rationale for choosing YU2 for the generation of
immunogens. Neutralizing antibodies raised against a
neutralization-resistant viral isolate appear to have a greater
propensity to neutralize other viral isolates than antibodies
directed against a more neutralization-sensitive viral isolate
(Yang et al., 2001).
C. Grundner et al. / Virology 331 (2005) 33–4642Since we were encouraged by these data, we continued to
boost both the soluble gp140 (/GCN4) rabbits (group B)
and the EnvPL-inoculated rabbits (group D). Interestingly,
although the ELISA titer of the group B rabbits did not
show a large increase, the neutralizing titer for three of the
rabbits showed an increase in potency against the 89.6, BaL
and JR-CSF isolates. That we boosted neutralizing
responses without large increases in binding antibodies
suggests that the soluble trimer preferentially presented
relevant epitopes and drove relevant responses. This inter-
pretation is supported by an increase in homologous neutra-
lization of the EnvPL rabbits that were inoculated the 5th time
with EnvPL and the 6th with the soluble gp140 (/GCN4)
trimers.
We utilized purified immunoglobulins to demonstrate
conclusively that the neutralizing activity was IgG-medi-
ated and concentration-dependent. Interestingly, antibodies
isolated from the sera of rabbit 16 (gp140 (/GCN4)
group B) displayed no neutralizing activity prior to
purification of the IgG. However, following purification,
the IgG neutralized SF162 at the 10 mg/ml concentration.
This slight gain in potency could simply be due to an
effective increase in immunoglobulin concentration follow-
ing IgG purification or could be due to the elimination of
components in the sera that masked a weak, but specific,
neutralizing activity. In any case, this example illustrates
that purification of the IgG from sera may have a positive
influence on the detection of neutralizing activity. The
rabbit 16 IgG also weakly neutralized the homologous
YU2 strain, but upon serial dilution of the IgG, YU2 entry
was enhanced. At the highest concentration tested, the
immunoglobulin from this animal also enhanced JR-FL
entry. Enhancement of HIV-1 infection by antibodies
binding at sub-saturating concentrations has been well
described (Homsy et al., 1989; Lund et al., 1995;
Robinson et al., 1988; Sullivan et al., 1995, 1998a; Takeda
et al., 1988), but the exact mechanisms are unknown. One
model suggests that antibodies at sub-saturating concen-
trations may induce Env conformational changes that may
allow for more efficient binding to the cellular receptors.
Enhancement could be interpreted as an initial effect of
inadequate antibody binding to virions that then proceeds
towards neutralization at higher antibody concentrations.
Apparently, sera or IgG that display enhancement at the
concentrations tested (Table 4) do not possess high enough
levels of antibodies that bind to the functional spike to
achieve neutralization. In this model, enhancement at least
indicates that there are antibodies elicited that can bind to
envelope glycoprotein spikes, albeit at levels too low to
neutralize. Other models of enhancement include antibody
binding to Fc receptors to stabilize the interaction of the
virus and the target cell receptors, providing a nonspecific
binding component (Tirado and Yoon, 2003). Comple-
ment-mediated modes of HIV-1 enhancement have also
been proposed (Tirado and Yoon, 2003), but are unlikely
in the neutralization format used in this and most studies.As enhancement of HIV-1 infection by Fab fragments has
been reported, some mechanisms of enhancement must be
independent of Fc-mediated effects.
Analysis of the sera and purified IgG allowed us to detect
neutralization of 8 of the 13 isolates analyzed in this study
by the gp140 (/GCN4)-elicited immunoglobulins (7 of 13
were inhibited by two animals or more, including HXBc2).
All sera that displayed neutralizing activity prior to
purification were able to yield IgG of equal or enhanced
neutralization potency, validating the controls and methods
used to identify immunoglobulin-mediated viral neutraliza-
tion in the sera.
When we performed V3 loop adsorptions of anti-Env
sera or IgG for either the soluble gp140 molecules or the
EnvPLs, most animals displayed a modest reduction in their
neutralizing activity. We interpreted these results to indicate
that most of the trimer-elicited neutralizing activity is not
directed against the V3 loop. However, it is possible that not
all V3 loop-directed neutralizing activity was removed by
V3 loop peptide adsorption. The data also seemed to
indicate that the EnvPLs had slightly less breadth of
neutralization and a slightly greater level of V3-loop
directed neutralizing antibodies (Table 5). Since the V3
loop is often an immunodominant region of gp120, either
the YU2 envelope glycoproteins do not efficiently present
the V3 loop or the trimeric constructs obscure or dampen
V3-directed antibody responses.
Several factors may account for the better elicitation of
neutralizing antibodies by the trimeric envelope glyco-
protein formulations, including a diminution in the
immunodominance of the V3 region. In addition, many
epitopes available for antibody binding on monomeric
gp120, such as the gp120–gp41 interface and regions
along the trimer axis, elicit non-neutralizing antibodies,
because these epitopes are not accessible on the functional
spike. The presentation of trimeric spikes to the immune
system may also limit the number of irrelevant epitopes
that are likely presented to the immune system by the
conformationally flexible monomeric gp120 (Kwong et
al., 2002; Myszka et al., 2000). This study strongly
supports the concept that trimeric envelope glycoprotein
formulations, either soluble or on a solid phase, are more
efficient in eliciting broadly neutralizing antibodies than
gp120 in outbred animals. In contrast to the results
obtained with gp120, additional boosting of the rabbits
with trimeric HIV-1 envelope glycoproteins resulted in
progressive improvement in the breadth and potency of
neutralizing activity. The less efficient elicitation of
neutralizing antibodies observed with EnvPLs compared
to YU2 gp140 (/GCN4) may be due to the smaller dose
of envelope glycoproteins inoculated. The EnvPL format
may hold promise in immunogen design if the current
dose-related limitations can be overcome. These findings
support the continued study of trimeric envelope glyco-
protein formulations as platforms for the design of
improved HIV-1 vaccine components.
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Envelope glycoprotein constructs used for the generation of
EnvPLs
The envelope glycoprotein constructs for the generation
of EnvPLs were derived from the primary R5 HIV-1 isolates
YU2 and JR-FL, and the X4, TCLA isolate HXBc2, as
described previously (Grundner et al., 2002). The coding
sequences for the 89.6 envelope glycoproteins were
obtained from the pSVIIIenv 89.6 expression plasmid
(Sullivan et al., 1998b). A cytoplasmic tail truncation was
generated by introduction of a stop codon in place of the
codon for amino acid 712 (HXBc2 numbering). The C9
peptide tag was added by appending the sequence encoding
the peptide TETSQVAPA to the C-termini of all constructs
according to the QuikChange (Stratagene) protocol. To
create covalently linked gp120–gp41 glycoproteins, the
proteolytic cleavage site between gp120 and gp41 was
deleted by replacing the arginines 508 and 511 with serines
by QuikChange site-directed mutagenesis. The resulting
constructs encoding cleavage-deficient gp160DCT envelope
glycoproteins were subsequently used to generate the
EnvPLs. Amino acid residue numbers are designated
according to the prototypic HXBc2 sequence, according to
current convention. The introduction of the desired muta-
tions was confirmed by DNA sequencing.
Expression of EnvPL and monomeric HIV-1 envelope
glycoproteins
Envelope glycoproteins for the generation of EnvPLs
were expressed as previously described (Grundner et al.,
2002). Briefly, 293T cells were transiently transfected with
plasmids expressing the gp160DCT glycoproteins using
Effectene reagent (QIAGEN) and, for the YU2 and 89.6
envelope glycoproteins, the HIV-1 Tat expressor plasmid
pSVTat. Cells were harvested 48 h after transfection, using
phosphate-buffered saline (PBS) containing 5 mM EDTA.
Monomeric YU2 gp120 was expressed from codon opti-
mized env sequences cloned into the CMV-driven
pCDNA3.1 expressor plasmid (Stratagene) and transient
transfection of 293T cells by Fugene6 (Roche). Following
expression in serum-free medium for 5 days, YU2 gp120
was purified to homogeneity over an F105 affinity column
(not shown).
Expression and purification of gp140 ()GCN4
glycoproteins
To produce soluble YU2 gp140 (/GCN4) proteins, the
serum-free-medium-adapted cell line, 293F, (Invitrogen,
Carlsbad, CA) was transiently transfected in DMEM
medium supplemented with 10% heat-inactivated fetal calf
serum (HIFCS) and 0.1 mMMEM non-essential amino acids
solution (Invitrogen), with the pCDNA3.1()YU2gp140(/GCN4) plasmid. Lipofectamine2000 (Invitrogen) was
used to transfect the plasmid DNA as per manufacturer’s
instructions. One day after transfection, fresh serum-free 293
SFM II medium (Invitrogen) was used to replace serum-
containing medium. The cell culture supernatants were
collected daily, until the 6th day post-transfection. The
YU2 GCN4 envelope glycoproteins were purified from the
supernatants with an IgGb12 antibody affinity column,
eluted from the column with 3 M MgCl2 containing 20
mM Tris–HCl, pH 7.4 and dialyzed three times against 2 l of
PBS containing 0.5 M NaCl. The proteins were concentrated
with AmiconUltra 30,000MWCOCentrifugal Filter Devices
(Millipore, Bedford, MA) and analyzed by SDS PAGE, gel
filtration and Blue native gels. As analyzed by reducing and
non-reducing SDS gels, the YU2 gp140 (/GCN4) proteins
were highly pure, exceeding 95% homogeneity (not shown).
By gel filtration over Superdex 200 or Superose 6 columns
and Blue native gels, the proteins were predominantly
(approximately 70%) of a molecular weight consistent with
trimer as previously reported ((Yang et al., 2000b) and data
not shown). The majority of the remainder of the protein
oligomers was of a molecular weight consistent with a
dimer of trimers, with a small fraction of protein
aggregates. The oligomeric mixture from the affinity
column was used for inoculations to generate the sera
analyzed in this study.
Generation of EnvPLs
EnvPLs containing the envelope glycoproteins from the
HIV-1 molecular clones HXBc2, 89.6, JR-FL, and YU2
were generated as described previously (Grundner et al.,
2002) with the following modifications. Dynabeads with a
diameter of 2.8 Am (M-280) were used for capturing the C9-
tagged envelope glycoproteins. The lipid mixture used for
the reconstitution of a lipid membrane around the PLs
consisted of the lipids 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-
Phosphocholine (POPC), 1-Palmitoyl-2-Oleoyl-sn-Glycero-
3-Phosphoethanolamine (POPE) and Dimyristoylphosphati-
dic acid (DMPA) in a ratio of 6:3:1 and 1% of the head
group-modified synthetic lipid 1,2-dioleyl-sn-glycero-3-
phosphoethanolamine-n-(biotinyl) (Biotinyl-DOPE). All
lipids were obtained from Avanti Polar Lipids. Before each
inoculation, the PLs were tested for envelope glycoprotein
incorporation by FACS analysis. The presence of a lipid
membrane around the EnvPLs was confirmed by FACS
analysis detecting biotinylated lipids incorporated into the
membrane with avidin-FITC (Sigma).
Immunization of rabbits
Groups of five New Zealand White rabbits were
inoculated intradermally with 1 ml of monophospholipid
A + trehalose dicorynomycolate + cell wall skeleton of
tubercule bacillus (MPL+TDM+CWS) Ribi adjuvant emul-
sion (Sigma) containing the respective antigen. The amounts
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glycoprotein in each inoculum were adjusted to the same
molar quantity of the gp120 moiety. Thus, each rabbit
received 18.9 Ag of YU2 gp120 and 25 Ag of YU2 gp140
(/GCN4). Animals inoculated with EnvPLs received 1 ml
MPL+TDM+CWS adjuvant emulsion containing approxi-
mately 1.8  109 M-280 EnvPLs at 4 to 6 separate dorsal
sites. Boosting inoculations were administered 2, 6, 10, 22,
and in some cases, 34 weeks after the initial inoculation. Ear
bleeding was performed 13 days after the second and 7 days
after the fourth and fifth inoculation. The blood was
incubated O/N at 4 8C in a Vacutainer SST Gel Clot
Activator (Becton Dickinson) and spun for 30 min at
2000  g at 4 8C. The cleared serum was collected and
incubated for 30 min at 55 8C to inactivate complement.
The sera were then stored at 20 8C.
Purification of rabbit immunoglobulins (IgG)
Rabbit IgG was purified from rabbit sera with the T-Gel
Purification Kit (Pierce, Rockford, IL), which purifies the
IgG at nearly neutral pH per manufacturer’s instructions.
Briefly, 87 mg of potassium sulfate was added to 1 ml of
rabbit serum until fully dissolved at room temperature
(RT). The serum sample was centrifuged at 10,000  g for
20 min, and the supernatant was applied on a T-gel column
pre-equilibrated with binding buffer (0.5 M potassium
sulfate, 50 mM sodium phosphate, pH 8.0), washed with
binding buffer, and eluted with elution buffer (50 mM
sodium phosphate, pH 8.0). Upon elution, the buffer was
exchanged with PBS, and IgGs were concentrated with
Centricon Plus 20 100,000 MWCO concentrators (Milli-
pore). The concentration of each IgG sample was
determined by UV absorbance at 280 nm, and adjusted
to 50 mg/ml final concentration for the virus neutralization
assay.
ELISA for the detection of anti-gp120 reactivity in rabbit
serum
To determine the anti-gp120 reactivity in sera from
immunized animals, 100 ng of affinity-purified mamma-
lian-expressed YU2 gp120 in PBS was adsorbed onto each
well of a high-protein-binding microwell plate (Corning)
overnight at 4 8C. After blocking the plates with 100 Al
blocking buffer (PBS with 2% dry milk and 5% HIFCS),
serial serum dilutions in ELISA blocking buffer were
incubated in each well for 1 h at RT. After three washes
with PBS/0.2% Tween-20, a secondary Anti-Rabbit-IgG-
HRP antibody (Sigma) was added in washing buffer at a
1:5000 dilution for 1 h at RT. Following three washes, the
ELISAs were developed with 100 Al TMB Peroxidase
substrate (KPL). The reaction was stopped by adding 100
Al 1 M HCl to each well. The optical density at 450 nm
was read on a microplate reader (Molecular Devices).
Endpoint titers were defined as the last reciprocal serumdilution at which the absorption at 450 nm was greater
than two-fold over the signal detected with pre-immune
serum.
HIV-1 single-round neutralization assays
The single round intracellular p24-antigen flow cyto-
metric HIV-1 neutralization assay has been described
previously (Mascola et al., 2002a). Because animal sera
can exhibit a degree of nonspecific effects on HIV-1
neutralization assays ranging from slight enhancement of
infection to occasional nonspecific neutralization (data not
shown and John Mascola, personal communication), we
sought to control for such activities in a rigorous manner in
our methods development. To be able to assess the bona fide
neutralizing reactivity in individual sera relative to the
baseline activity of pre-immune serum in these animals, sera
were tested individually and compared to the corresponding
individual pre-immune sera.
The assay was performed by incubating 40 Al of virus
stock in 96-well culture plates with 10 Al of heat-
inactivated rabbit serum or purified IgG in duplicate.
This volume of virus represented a multiplicity of
infection of approximately 0.1 and roughly 20,000
TCID50 (determined by a 14-day titration assay) of HIV
in each well. Following incubation for 30 min at 37 8C,
20 Al of peripheral blood mononuclear cells (PBMC;
1.5  105 cells) were added to each well. PBMC were
maintained in IL-2 culture medium containing 1 AM
indinavir, and the cells were fed on day 1 with 150 Al of
Il-2 culture medium containing indinavir. One day after
infection, permeabilized cells were stained for intracellular
p24-Ag using the KC57 anti-p24 antibody, followed by
quantitation of HIV-1 infected cells by flow cytometry.
The percentage of neutralization was defined as reduction
in the number of p24-positive cells compared with the
number in well incubated with corresponding pre-immune
serum. For example, if there was a 30% reduction of p24-
positive cells by the addition of pre-bleed serum, then the
post-immune serum neutralization was calculated from
this reduced level of viral entry to take into account non-
specific serum effects. Besides the pre-bleed negative
control, every assay always includes at least two concen-
trations of the monoclonal antibodies 2G12 and 2F5 and
HIVIgG as positive controls to ensure reproducible
results.
For the measurement of infection with pseudotyped GFP
reporter viruses, infected cells were washed once in FACS
buffer and directly detected. Live cells initially gated by
forward and side scatter were analyzed for intracellular
expression of p24-Ag or GFP. The number of p24-Ag-
positive cells or GFP-positive cells was determined using a
bivariate plot of fluorescence versus forward scatter; the
gate was set on mock-infected cells. To enumerate infected
PBMC, cells were washed, fixed and permeabilized, and
stained with the KC57 anti-p24 antibody. After forward and
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Final quantitation of p24-Ag-positive cells was done by
subtraction of background events in mock-infected PBMC
(usually less than 10 positives per 50,000 events). The
percent neutralization was defined as reduction in the
number of p24-Ag-positive cells and GFP-positive cells,
respectively, compared to the number in control wells with
individual prebleed serum or no antibody, respectively.
To obtain the IC50 and IC80 data, serial dilutions of anti-
serum or IgG were incubated with virus as described
above. Anti-serum dose–response curves were fit with a
nonlinear function, and the inhibitory dilution that neu-
tralized 50% and 80% (IC50 and IC80 respectively) of virus
was calculated by a least-squares regression analysis.
Statistical analysis of IC50 titers was performed using the
non-parametric Mann Whitney rank order test (GraphPad
Prism software package V3.0, GraphPad Software, Inc.
San Diego, CA).
V3 loop adsorption assays
Peptides corresponding to the BaL and YU2 V3 loops
were purchased from SynPep (Dublin, CA). Both are 23mers
starting with sequence TRPNNN and were provided at N95%
purity by HPLC. V3 competition studies were performed in
the format of the standard neutralization assay by incubating
rabbit sera with the indicated peptide at a concentration of
15–30 Ag/ml (6–12 AM) for 30 min at 37 8C prior to the
addition of virus. Controls included mock peptide (PBS) and
a mixture of Ebola envelope 15mer peptides and a scrambled
V3 loop peptide (IGPGRAFTKPNNNFYTTGTRKSIH).
Initial studies had indicated that concentrations of the
BaL and YU2 peptides equal to or exceeding 15 Ag/ml
could completely block anti-V3 mAb 447-mediated neu-
tralization of SF162 viral entry (Fig. 3 and data not
shown). These peptides could also block approximately
90% of the neutralizing activity of the V3 loop-directed
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